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OBJECTIVE — The purpose of this study was to assess factors associated with patient fre-
quency of intentionally skipping insulin injections.
RESEARCH DESIGN AND METHODS — Data were obtained through an Internet
survey of 502 U.S. adults self-identiﬁed as taking insulin by injection to treat type 1 or type 2
diabetes. Multiple regression analysis assessed independent associations of various demo-
graphic, disease, and injection-speciﬁc factors with insulin omission.
RESULTS — Intentional insulin omission was reported by more than half of respondents;
regular omission was reported by 20%. Signiﬁcant independent risk factors for insulin omission
were younger age, lower income and higher education, type 2 diabetes, not following a healthy
diet, taking more daily injections, interference of injections with daily activities, and injection
pain and embarrassment. Risk factors differed between type 1 and type 2 diabetic patients, with
diet nonadherence more prominent in type 1 diabetes and age, education, income, pain, and
embarrassment more prominent in type 2 diabetes.
CONCLUSIONS — Whereas most patients did not report regular intentional omission of
insulin injections, a substantial number did. Our ﬁndings suggest that it is important to identify
patients who intentionally omit insulin and be aware of the potential risk factors identiﬁed here.
For patients who report injection-related problems (interference with daily activities, injection
pain, and embarrassment), providers should consider recommending strategies and tools for
addressing these problems to increase adherence to prescribed insulin regimens. This could
improve clinical outcomes.
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M
ore than 25% of people with dia-
betes take insulin (1). The Amer-
ican Diabetes Association and the
European Association for the Study of Di-
abetes recently issued a consensus algo-
rithm for management of type 2 diabetes
identifying insulin as the most effective
glucose-lowering agent (2). Lower com-
pliance with insulin regimens is associ-
ated with higher A1C levels (3,4) and
with higher rates of hospital admissions
for diabetes-related complications (3).
Despitetheimportanceofadheringto
prescribed insulin regimens, little is
knownaboutthedegreetowhichpatients
are adherent or about factors associated
with adherence. In a study using a De-
partment of Veterans Affairs database, in-
sulin use was 77% of prescribed amounts
(3). In this population, two-thirds of
whom were 65 years of age, age did not
predict insulin regimen adherence, and
adherence was nearly identical for men
and women, but non-Hispanic white pa-
tients were more adherent than patients
who were African American or Hispanic.
Inanotherstudyofpatientswhoswitched
from using a syringe to deliver insulin to
usingapen,36%ofthepatientshadmed-
ication possession rates of 80% while
using a syringe, but this rose to 55% after
switching to a pen (5).
A recent review identiﬁed factors as-
sociated with adherence to any diabetes
medication (6). These factors include
medication costs, regimen complexity,
the patient’s emotional well-being, and
the patient’s perceptions of medication
side effects and medication-related intru-
sions on activities of daily living.
Medication costs can affect adherence.
InaU.S.surveyofadultswithtype2diabe-
tes using glucose-lowering agents, 11% re-
ported that they had cut back on their
medication in the past year (7). Adherence
rates are also affected by regimen complex-
ity. Rates of adherence for oral diabetes
medication decline with the number of
times each day the medication should be
taken (8), but we could ﬁnd no report on
the association between insulin injection
frequency and insulin omission. Depres-
sion also has been associated with diabetes
medication nonadherence (9) and with in-
sulin omission among adolescent females
(10).
Several researchers have developed
questionnaires to assess patient percep-
tions of insulin therapy that could affect
regimen adherence (11–16). These ques-
tionnaires assess factors such as 1) inter-
ference with eating, exercise, and
activities of daily living; 2) dissatisfaction
withtheamountoftimerequiredtoadmin-
isterinsulinandwithinjection-relatedpain,
bruising, and embarrassment; 3) worries
aboutinsulin-relatedsideeffectssuchashy-
poglycemia; and 4) negative affect associ-
ated with administering insulin. Un-
fortunately, none of these studies formally
assessed the association between any of
these factors and intentional insulin omis-
sion.However,arecentpublicationdidﬁnd
that insulin adherence is lower among
young women who are concerned about
their weight (17).
The current study is designed to ad-
dress questions about intentional insulin
omission, including the frequency of this
behavior and factors hypothesized to be
associated with this behavior, in a large
sample of patients weighted to be repre-
sentative of all adult diabetic patients in
the U.S. who take insulin. In a previous
report, we found that most insulin-
treated patients wanted to reduce the
number of insulin injections they take
each day, and some reported that injec-
tion-related problems affect the number
of injections they are willing to take (18).
Here we formally assess the impact of a
broad range of factors that might be ex-
pected to inﬂuence intentional insulin
omission, including demographic and
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den of insulin therapy (i.e., interference
with activities of daily living), the injec-
tionexperience(e.g.,painandembarrass-
ment), and negative emotions (e.g.,
dread) associated with insulin injections.
RESEARCH DESIGN AND
METHODS— Data were obtained
through an Internet survey of U.S. adults
self-identiﬁed as taking insulin to treat
type 1 or type 2 diabetes; the survey was
conducted13Juneto7July2008byHar-
ris Interactive, a contract research organi-
zation. The sample was drawn from the
Harris Interactive Chronic Illness Panel.
Patients were recruited by email if they
had diabetes and currently used a syringe
or insulin pen to deliver insulin. The re-
cruitment quota was 500 participants.
Institutional review board approval
for the study protocol was obtained from
the Human Subject Research Committee
of Loyola University Maryland.
Measures
Data collected from participants included
the following: 1) basic demographic infor-
mation;2)diseasetype,duration,complica-
tions,andtreatment;3)perceivedburdenof
insulin injections; 4) the experience of in-
jections;5)negativeaffecttowardinsulinin-
jections; and 6) frequency of skipping
insulin injections. Respondents reported
whethertheyhadeverbeendiagnosedwith
type 1 or type 2 diabetes, depression, obe-
sity, or cardiovascular disease (“high blood
pressure” or “heart disease”) and whether
they treat their diabetes with diet, exercise,
and medications. Other measures are de-
scribed below.
Burden of injections. Interference with
eating and exercise was measured as the
mean of two items asking, “How much
does the way you inject insulin interfere
with eating/exercising when you want?”
(response options: 1  not at all, 2  a
little,3amoderateamount,4agreat
deal). The reliability of this scale was
moderate (0.80). Interference with
activitiesofdailylivingwasmeasuredasa
count of the afﬁrmative responses to the
question,“Doyourinsulininjectionshave
a negative effect on: social activities, rec-
reational activities, sexual activity, work/
career, family care-giving?” (possible
range  0–5). Another measure of inter-
ferencewaswhethertherespondentplans
daily activities around insulin injections
(1  yes, 0  no).
Experience of injections. There were
ﬁve measures—dissatisfaction with in-
jection time needed, ease of use, pain,
inﬂammation/bruising, and embarrass-
ment—each measured by a single item
(response options: 1  very satisﬁed, 2 
satisﬁed,3somewhatsatisﬁed,4not
at all satisﬁed).
Negative affect toward insulin injec-
tions was measured as the mean of three
items:“Idreadinsulininjections”;“Inject-
ing myself with insulin is the hardest part
ofmanagingmydiabetes”;“Ihavetomen-
tallypreparemyselfbeforeeachinjection”
(response options: 1  strongly disagree,
2  somewhat disagree, 3  somewhat
agree, 4  strongly agree). The reliability
of this scale was moderate (0.85).
Worry about hypoglycemia was mea-
sured by a single item (response options:
1  never, 2  rarely, 3  sometimes,
4  often).
Frequency of intentional insulin omis-
sion. The dependent variable in this
study was the response to the question,
“How often do you skip insulin injections
that you know you should take?” (re-
sponse options: 1  never, 2  rarely,
3  sometimes, 4  often).
Statistical analysis
The sample was weighted to be represen-
tative of the U.S. population of people
with diabetes. Multiple regression analy-
sis was used to assess independent rela-
tionships with frequency of skipping
insulin injections. Control variables (de-
mographic and disease characteristics)
were entered ﬁrst, and then injection-
related experience and attitudes were en-
tered using stepwise criteria (P  0.05).
Separate analyses were performed in the





The sample (n  502) was 55% male,
73% white, 11% Hispanic, 11% African
American, and 5% other race/ethnicity,
with a mean age of 55 years (Table 1).
About half (51%) had attended college.
Only about one-third (38%) were pres-
ently employed, and those who were not
employed included 8% students and 8%
disabled; the remainder were mostly re-
tired or nonworking spouses. Median an-
nual income of the sample was about
$35,000.
Approximately one-third (32%) re-
ported having been diagnosed by a health
care professional as having depression. A
total of 77% of the sample said they had
type 2 diabetes, and the rest said they had
type 1 diabetes; patients reported having
diabetesforanaverageofalmost15years.
A total of 61% of the patient sample
identiﬁed a primary care physician as
their primary diabetes health care pro-
vider, whereas 28% named an endocri-
nologist and 11% named another
(nonphysician) health care provider. Of
the sample, 39% reported engaging in
physical activity and 55% said they fol-
lowed a healthy diet. A total of 70% of
patients surveyed said they took insulin
using a syringe and 30% said they used
a pen; most (56%) changed their needle
with each injection. Patients reported
taking an average of 2.7 injections a day
(maximum of ﬁve recorded).
Asubstantialminorityofrespondents
(22%) said they planned their daily activ-
ities around their insulin injections, and
similar proportions reported that insulin
injections interfered with their lives: 23%
said insulin injections interfered with
their eating/exercising schedule more
than a little, and 25% said that insulin
injections had a negative effect on one or
more activity of daily living. Further, a
substantial minority of respondents
(22%) reported they had to mentally pre-
pare themselves before each injection,
and33%identiﬁedtheyhadsomelevelof
dread associated with taking their daily
injections.
Attitudinal measures tended to fall
below the halfway point of the response
options (i.e., 2.5). Respondents re-
ported moderate levels of satisfaction
with the pain and the inﬂammation and
bruising associated with insulin injec-
tions (the scores for pain and inﬂamma-
tion/bruising were signiﬁcantly higher
than those for embarrassment, time
needed, and ease of use, P  0.001). A
quarter (24%) of respondents had a score
representing negative affect toward injec-
tions (they scored above the midpoint on
the scale), and 21% reported “often” wor-
rying about hypoglycemia.
Regression analysis
Over half (57%) of respondents reported
skipping insulin injections they knew
they should take; 20% report skipping
them sometimes or often. Table 2 shows
the results of the regression analysis of
intentional insulin omission frequency.
Control variables (demographic and dia-
betes characteristics) accounted for 26%
of the variance in intentional insulin
omission. Older respondents, those who
Peyrot and Associates
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All respondents Type 1 diabetes Type 2 diabetes
N 502 114 388
Sex
M 55 41% 59%
F 45 59% 41%
Race/ethnicity
White 73 70% 74%
Hispanic 11 19% 9%
African American 11 8% 12%
Other 5 3 5
Current age (years) 54.9  13.9 46.9  15.6 57.5  12.2
Education
No college 49 24 44
Some college 28 38 26
College graduate 14 17 13
Graduate school 9 21 17
Employment
Full-time employment 28 33 27
Part-time employment 10 16 8
Not employed (student) 8 14 7
Not employed (disabled) 8 2 10
Other 46 35 48
Household income ($)
15,000 23 23 23
15,000–24,999 11 5 12
25,000–34,999 10 10 10
35,000–49,999 13 11 14
50,000–74,999 16 12 17
75,000 13 25 10
No answer 14 14 14
History of depression 32 30 33
History of cardiovascular disease 71 58 75
History of obesity 36 20 41
Duration of diabetes (years) 14.8  10.2 21.4  13.0 12.8  8.3
Diabetes care provider
Primary care physician 61 46 66
Endocrinologist 28 48 22
Nonphysician 11 6 12
Engage in physical activity 39 55 34
Follow healthy diet 55 65 52
Insulin injection device
Pen 30 33 29
Syringe 70 67 71
Change needle each use 56 50 58
Daily injection frequency 2.7  1.4 3.5  1.3 2.5  1.3
Plan daily activities around insulin injections 22 32 19
Interference with eating and exercise* 1.7  0.8 1.9  0.8 1.6  0.8
Interference with activity of daily living* 0.5  1.0 0.7  1.3 0.5  1.0
Dissatisfaction with time needed for injection† 2.0  0.9 1.9  0.9 2.1  0.9
Dissatisfaction with injection ease of use† 2.0  0.9 1.9  0.9 2.0  0.9
Dissatisfaction with injection pain† 2.3  0.9 2.2  0.9 2.3  0.9
Dissatisfaction with injection inﬂammation/bruising† 2.4  1.0 2.4  0.9 2.5  1.0
Dissatisfaction with injection embarrassment† 2.0  0.9 2.1  0.9 2.0  0.9
Negative affect toward injections‡ 1.8  0.9 1.6  0.7 1.9  0.9
Worry about hypoglycemia* 2.7  0.9 2.8  1.0 2.7  0.9
Skip insulin injections§ 1.8  0.8 1.7  0.7 1.8  0.8
Data are % or means  SD, unless otherwise stated. *1  not at all, 2  a little, 3  a moderate amount, 4  a great deal. †1  very satisﬁed, 2  satisﬁed, 3 
somewhat satisﬁed, 4  not at all satisﬁed. ‡1  strongly disagree, 2  somewhat disagree, 3  somewhat agree, 4  strongly agree. §1  never, 2  rarely, 3 
sometimes, 4  often.
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hold income, and those who followed a
healthy diet were signiﬁcantly less likely
to skip injections, whereas subjects who
were students and had the highest educa-
tion or type 2 diabetes and subjects who
took more injections were signiﬁcantly
more likely to skip injections.
Four measures of injection burden
and experience had signiﬁcant indepen-
dent associations with higher levels of in-
tentional insulin omission and accounted
for an additional 10% of the variance.
These included two aspects of interfer-
ence (planning one’s activities around in-
sulin injections and injections interfering
with activities of daily living) and two as-
pects of the injection process itself (pain
and embarrassment). Respondents who
planneddailyactivitiesaroundinsulinin-
jections, those who said that taking injec-
tions interfered with activities of daily
living, and those who reported injection-
related pain or embarrassment intention-
allyskippedinsulininjectionsmoreoften.
Separate analyses using the variables
listed in Table 2 were performed among
subjects with type 1 diabetes and subjects
with type 2 diabetes (results not shown).
Because there were more participants
with type 2 diabetes, the overall model
most closely resembled that for type 2 di-
abetes. Only two variables signiﬁcant in
the overall model were not signiﬁcant in
the type 2 model—being a student and
following a healthy diet. Only three vari-
ables were signiﬁcant in the type 1 mod-
el—following a healthy diet, number of
daily insulin injections, and interference
with activities of daily living (being a stu-
dent had a P value of 0.056).
CONCLUSIONS— This study sug-
gests that intentional omission of insulin
injectionsthatshouldbetakenoccursinthe
majorityofadultsusinginsulintotreattheir
diabetes and is common in 20% of these
individuals. Intentional insulin omission
among adults varies with a number of de-
mographic and disease characteristics. It
also is associated with indicators of per-
ceived burden and the experience of injec-
tions as painful and embarrassing.
Demographic and disease factors
We found that respondents with higher
household income, but not individuals
with more education, were less likely to
skip insulin injections they knew they
shouldtake.Thismayreﬂecteasieraccessto
medications and supplies among individu-
als with higher income, but it is also likely
that higher socioeconomic status is associ-
ated with more access to diabetes educa-
tion, higher health literacy, greater control
over one’s daily routines, and better prob-
lem-solving skills (19). Our study appears
to be among the ﬁrst to identify an associa-
tion between socioeconomic status and in-
sulinomission.Futureresearchshouldseek
to identify potential mediators of this rela-
tionship, i.e., what links lower socioeco-
nomic status to insulin omission.
Contrary to earlier reports (3,4), we
found no racial/ethnic differences in inten-
tional insulin omission. This may be be-
cause we did not have enough nonwhite
respondents to examine the different racial/
ethnic groups separately. Alternatively, this
may be due to our controlling for income
andeducationintheanalysis,therebyelim-
inating the confounding of race/ethnicity
with socioeconomic status.
Much prior research has suggested that
intentional insulin omission is common
among female adolescents with type 1 dia-
betes, serving as a weight control strategy
and sometimes linked to eating disorders
(10). We found that students (who were
younger than nonstudents) were more
likely to skip injections they knew they
shouldtake,butthisbehaviorwasnotmore
commonamongwomenthanitwasamong
men. We found no overall association be-
tween age and intentional insulin injection
omissionamongpatientswithtype1diabe-
tes, suggesting that patients with type 1 di-
abetes “age-out” of this behavior by early
adulthood, when they complete their edu-
cation. Ascertaining the validity of this in-
terpretation would require following youth
with type 1 diabetes as they age into adult-
hood to determine change in rate of insulin
omission.
Our ﬁnding that, among individuals
with type 2 diabetes, older respondents
werelesslikelytoskipinsulininjectionsis
consistent with earlier studies (3,4). This
Table 2—Multiple regression analysis of frequency of insulin injection omission
BS E Signiﬁcance
Female sex* 0.045 0.067 0.028 0.499
White race/ethnicity† 0.006 0.073 0.003 0.936
Current age (years) 0.015 0.003 0.256 0.001
Education‡
Some college 0.001 0.076 0.001 0.990
College graduate 0.023 0.100 0.010 0.818
Graduate school 0.305 0.121 0.109 0.012
Employment§
Not employed (student) 0.273 0.125 0.094 0.030
Not employed (disabled) 0.317 0.120 0.107 0.009
Part-time employment 0.136 0.104 0.051 0.192
Full-time employment 0.108 0.078 0.061 0.166
Household income ($) 0.068 0.017 0.176 0.001
History of depression 0.048 0.072 0.028 0.504
History of cardiovascular disease 0.028 0.072 0.016 0.699
History of obesity 0.062 0.070 0.038 0.371
Type 2 diabetes  0.428 0.092 0.226 0.001
Duration of diabetes 0.001 0.004 0.019 0.686
Diabetes care provider¶
Endocrinologist 0.085 0.077 0.048 0.270
Nonphysician 0.169 0.102 0.066 0.096
Engage in physical activity 0.093 0.071 0.057 0.186
Follow healthy diet 0.157 0.069 0.098 0.023
Use insulin pen# 0.001 0.074 0.001 0.989
Needle change frequency 0.049 0.070 0.031 0.479
Daily injection frequency 0.118 0.025 0.205 0.001
Plan daily activities around insulin injections 0.247 0.079 0.129 0.002
Interference with activity of daily living 0.112 0.033 0.146 0.001
Dissatisfaction with injection pain 0.130 0.042 0.149 0.002
Dissatisfaction with injection embarrassment 0.146 0.041 0.169 0.001
*Referencecategorymale.†Referencecategorynonwhite.‡Referencecategorynocollege.§Reference
category  other not employed.  Reference category  type 1 diabetes. ¶Reference category  primary care
physician. #Reference category  use syringe.
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processes among individuals with type 1
and type 2 diabetes, but in type 2 diabe-
tes,thisprocesstakesplacelaterinthelife
course (almost all people with type 2 di-
abetesarediagnosedasadults).Ascertain-
ing the validity of this interpretation
would require following adults with type
2 diabetes as they age to determine
change in rate of insulin omission.
Having type 2 diabetes was itself as-
sociated with higher levels of intentional
omission of insulin injections. The beta
for this variable (0.226) was approxi-
matelytwicethesizeoftheunadjustedeta
(0.095), reﬂecting the fact that control-
ling for confounding factors (such as age
andnumberofdailyinjections)revealeda
stronger underlying association. The in-
dependent association of type 2 diabetes
with increased insulin omission may re-
ﬂect the fact that patients with type 2 di-
abetes have a residual insulin response,
reducing the immediate consequences of
omitting an injection. Thus, these indi-
viduals may feel less vulnerable to the ef-
fects of skipping insulin injections they
know they should take. Interestingly,
whereas duration of diabetes was associ-
ated with the frequency of insulin injec-
tion omission, regression analysis
revealed that duration of diabetes did not
makeanindependentcontributiontothis
behavior. That is, although insulin omis-
sion may be less common among individ-
uals with longer duration of diabetes, this
islikelyafunctionofotherfactorssuchas
age and type of diabetes rather than of
duration per se.
The associations of insulin injection
omission with other health conditions
were examined. Surprisingly, history of
depression was not associated with insu-
lin omission; this contradicts ﬁndings
from studies of general adherence (9,20)
and of insulin omission among adoles-
cents (10). However, because current de-
pressionwasnotassessed,anyconcurrent
association was likely to be lost. Others
have shown that depression symptom
scores ﬂuctuate substantially over rela-
tively short periods of time; individuals
with elevated depression symptoms at a
givenpointintimearelikelytonotreport
elevated symptoms 6 months later
(21,22). In addition, depression symp-
toms across the whole range of severity
symptoms have been shown to predict
regimen adherence more powerfully than
diagnosed depression (23). Being dis-
abled was associated with less insulin
omission; this may be due to a variety of
reasons, including their receiving more
assistance with care, or making a greater
effort to compensate for poor health.
Two aspects of patients’ treatment
regimens were associated with increased
insulin omission—respondents who took
more injections each day and those who
did not follow a healthy diet were more
likelytoskipinjections.Thatdietarynon-
adherence is associated with insulin non-
adherence is not surprising. More
frequent injection omission among indi-
viduals taking more injections could re-
ﬂect the frequently reported ﬁnding that
more complex regimens are associated
with lower levels of adherence (6). It
might also be that the impact of skipping
a shot is reduced among individuals who
take more shots.
Insulin and injection-related factors
Our study suggests that insulin omission
is affected by the perceived burden of in-
sulin therapy (i.e., having to plan one’s
life around insulin injections and feeling
that the insulin regimen interferes with
activities of daily living such as social ac-
tivities,work-relatedactivities,andfamily
care-givingresponsibilities).Weofferone
caveat regarding our ﬁndings; we do not
believethatthebehaviorofplanningone’s
day around insulin injections actually in-
creases the level of insulin injection omis-
sion, but we do believe that feeling that one
has to plan around one’s injections is asso-
ciatedwithhigherfrequencyofskippingin-
sulin injections one should take. That is,
whenthereisaconﬂictbetweenscheduling
of treatment and life activities, one can ei-
ther plan one’s activities in a way that re-
duces this conﬂict or deal with the conﬂict
by ignoring treatment needs. Reducing the
perceived burden of insulin injections may
requiremoreeffortfromhealthcareprovid-
ers. As we have suggested elsewhere, pro-
vidersmustﬁndoutwhatthespeciﬁcissues
are for each patient and work with that pa-
tient to develop solutions that will work for
him or her (24).
We note that the measure of interfer-
ence with eating and exercise was signiﬁ-
cantly associated with insulin injection
omission until interference with activities
of daily living was entered into the model
(results not shown). Thus, while interfer-
ence with eating and exercise might be
part of the burden of insulin therapy, in-
terference with other aspects of daily liv-
ing had a more substantial association
with insulin omission.
Our study suggests that insulin omis-
sion may be affected by the immediate
experience of injecting insulin as painful
and embarrassing (but not dissatisfaction
with time needed, ease of use, or skin in-
ﬂammation/bruising). There are numer-
ous device-related strategies for reducing
pain and embarrassment, including insu-
lin pens, ﬁner gauge needles, injection
ports, needleless injectors, and other in-
jection assistance devices. However, we
have found that patients do not feel that
their health care providers are giving
them adequate assistance in managing
these problems, even when they raise the
issue with their providers (18).
We note that the measure of negative
affect toward injections was signiﬁcantly
associatedwithinsulinomissionuntildis-
satisfactionwithinjectionembarrassment
and pain were entered into the model (re-
sults not shown). This suggests that ad-
dressing pain and embarrassment may
reduce not only insulin omission, but also
the emotional burden of injections, thereby
enhancingpsychologicalwell-being.Itisin-
teresting that worry about hypoglycemia
did not predict intentional omission of in-
sulin injections, even though worry about
hypoglycemia was high in the study popu-
lation. This suggests that patients may ad-
dressthisworrybyeatingmoreorlowering
insulin doses rather than by skipping injec-
tions altogether.
Study strengths and limitations
Strengths of the study include the large
sample of diabetic patients drawn from a
general population and the fact that the
samplewasweightedtobenationallyrep-
resentative. However, patients volunteer
for the panel from which respondents
were drawn and may not be representa-
tive of all patients (e.g., they may be more
adherent with their treatment regimens).
Limitations of the study include the
factthattherewasnoobjectivemeasureof
insulin use (e.g., pharmacy records).
Moreover, while our measure of insulin
omission was very speciﬁc (i.e., skipping
injections that respondents knew they
should take), it is possible that some re-
spondents included injections they did
not skip intentionally, but rather simply
forgot to take. Respondents might also
have included scheduled injections that




a healthy diet and fewer skipped injections.
More disciplined eating behavior reduces
meal skipping, which is an often-cited rea-
son for skipping insulin injections. This is
Correlates of insulin injection omission
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betweenourdietmeasureandinsulinomis-
sionispresentonlyamongindividualswith
type 1 diabetes where closer matching of
food and insulin is required.
Finally, our study probably underes-
timated the level of insulin nonadherence
in this population because it did not cap-
ture instances in which patients took an




Our ﬁndings make clear that while most
patients did not report regular omission
ofinsulininjections,asubstantialnumber
did. Thus, our ﬁndings suggest that it is
important to identify patients who omit
insulin and to be aware of the potential
risk factors identiﬁed here. Lack of per-
sonal resources (especially income) is one
potential warning sign. Although much
attention has been focused on insulin
omission among adolescents with type 1
diabetes, our ﬁndings suggest that among
adults, individuals with type 2 diabetes
are at higher risk. Patients who are not
adhering to other elements of the treat-
ment regimen, especially diet, also may
be at risk for insulin omission. For pa-
tients who report injection-related
problems (interference with daily activ-
ities, injection pain, and embarrass-
ment), providers should consider
recommending strategies and tools for
addressing these problems to prevent
insulin omission. This may contribute
to improved treatment adherence and
consequent clinical outcomes.
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